Key Highlights
- Vir Biotechnology shares are up nearly 7% in pre-market trading following its Q2 2026 results.
- Revenue came in at $238.9 million, sharply exceeding the $135.9 million consensus estimate.
- Adjusted EPS of $0.47 beat estimates by more than 75%, compared to a forecasted loss.
- Phase 2 data showed 88% of chronic hepatitis delta patients achieved undetectable viral RNA at Week 96.
- All three registrational ECLIPSE trials are now fully enrolled, with a $1.01 billion cash position.
Earnings Beat and Trial Data Lift Shares
Vir Biotechnology is trading higher in pre-market action after delivering a second-quarter report that beat expectations on both revenue and earnings, alongside encouraging new clinical data. Shares rose as much as 6.59% to $9.71 in pre-market trading, adding to a 3.03% gain from two sessions earlier, as investors digested the combination of financial strength and pipeline progress.
Revenue for the quarter reached $238.9 million, far above the $135.9 million analysts had expected, driven largely by collaboration and licensing payments tied to the company's partnership with Astellas. Adjusted earnings per share came in at $0.47, beating consensus estimates of a $0.83 loss by a wide margin.
Hepatitis Delta Program Advances
The company also reported updated Phase 2 SOLSTICE trial results in chronic hepatitis delta, its most advanced clinical program. Complete Week 96 data showed that 88% of patients receiving the combination of tobevibart and elebsiran achieved undetectable hepatitis delta virus RNA, compared with 53% of those on antibody monotherapy alone. A last-observation-carried-forward analysis produced an even higher 97% rate for the combination regimen, with no treatment-related serious adverse events reported.
All three registrational ECLIPSE trials evaluating the combination therapy are now fully enrolled, positioning the company to generate the data needed for potential regulatory submissions.
About Vir Biotechnology
Vir Biotechnology is a San Francisco based clinical stage biopharmaceutical company that develops therapies for serious infectious diseases and cancer. The company's technology platforms include a next generation antibody discovery engine and a T cell engager masking technology, supporting programs in chronic hepatitis delta, chronic hepatitis B, and multiple oncology indications. Vir maintains partnerships with companies including Gilead Sciences, GlaxoSmithKline, and WuXi Biologics.
Financial Position and Pipeline Outlook
Vir ended the quarter with roughly $1.01 billion in cash, equivalents, and investments, supported in part by $198.5 million in Astellas payments during the quarter. Research and development expense totaled $135.3 million, while the company projected its cash runway extending into the second half of 2028. Management also highlighted continued momentum in its oncology pipeline, including multiple expansion cohorts in prostate cancer under the Astellas partnership and additional trial data expected later this year.
Conclusion
Vir Biotechnology's combination of a substantial earnings beat and encouraging late stage trial data has given investors renewed confidence in the company's hepatitis delta program and broader pipeline. With strong cash reserves and multiple registrational trials fully enrolled, the company appears well positioned heading into key data readouts later this year.
Why is Vir Biotechnology stock up today?
Vir Biotechnology shares are trading higher after the company reported a significant second-quarter earnings beat and positive Phase 2 data in chronic hepatitis delta.
What were Vir Biotechnology's Q2 2026 results?
The company reported revenue of $238.9 million, well above consensus estimates, along with adjusted earnings per share of $0.47.
What is the significance of the SOLSTICE trial results?
Week 96 data showed 88% of chronic hepatitis delta patients achieved undetectable viral RNA using the combination of tobevibart and elebsiran, supporting the ongoing registrational ECLIPSE trials.
This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...